{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:36:11Z","timestamp":1793504171566,"version":"4.5.0"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01453-7","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:56:17Z","timestamp":1771995377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies"],"prefix":"10.1038","volume":"16","author":[{"given":"Tingting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1782-7322","authenticated-orcid":false,"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"1453_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02345-1","volume":"41","author":"A Haghtalab","year":"2024","unstructured":"Haghtalab A, Hejazi M, Goharnia N, Yekanlou A, Hazhir K, Barghi A, et al. Investigating the correlation between prominent viruses and hematological malignancies: a literature review. Med Oncol. 2024;41:102.","journal-title":"Med Oncol"},{"key":"1453_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.coviro.2016.07.007","volume":"21","author":"D Saha","year":"2016","unstructured":"Saha D, Wakimoto H, Rabkin SD. Oncolytic herpes simplex virus interactions with the host immune system. Curr Opin Virol. 2016;21:26\u201334.","journal-title":"Curr Opin Virol"},{"key":"1453_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2023.2188858","volume":"10","author":"D Luciola Zanette","year":"2023","unstructured":"Luciola Zanette D, Andrade Coelho KBC, de Carvalho E, Aoki MN, Nardin JM, Ara\u00fajo Lalli L, et al. Metagenomic insights into the plasma virome of Brazilian patients with prostate cancer. Mol Cell Oncol. 2023;10:2188858.","journal-title":"Mol Cell Oncol"},{"key":"1453_CR4","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/ajh.27430","volume":"99","author":"L Malpica","year":"2024","unstructured":"Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:2002\u201315.","journal-title":"Am J Hematol"},{"key":"1453_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ijc.33802","volume":"150","author":"Z Shen","year":"2022","unstructured":"Shen Z, Hu L, Yao M, He C, Liu Q, Wang F, et al. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group. Int J Cancer. 2022;150:327\u201334.","journal-title":"Int J Cancer"},{"key":"1453_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fonc.2019.00062","volume":"9","author":"H Kimura","year":"2019","unstructured":"Kimura H, Kwong YL. EBV viral loads in diagnosis, monitoring, and response assessment. Front Oncol. 2019;9:62.","journal-title":"Front Oncol"},{"key":"1453_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.82","volume":"47","author":"CY Ok","year":"2015","unstructured":"Ok CY, Li L, Young KH. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med. 2015;47:e132.","journal-title":"Exp Mol Med"},{"key":"1453_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/1568009623666230512153741","volume":"24","author":"X Huang","year":"2024","unstructured":"Huang X, Zhang M, Zhang Z. The role of LMP1 in Epstein-Barr virus-associated gastric cancer. Curr Cancer Drug Targets. 2024;24:127\u201341.","journal-title":"Curr Cancer Drug Targets"},{"key":"1453_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189218","volume":"1879","author":"M Alsaadawe","year":"2024","unstructured":"Alsaadawe M, Radman BA, Long J, Alsaadawi M, Fang W, Lyu X. Epstein Barr virus: a cellular hijacker in cancer. Biochim Biophys Acta Rev Cancer. 2024;1879:189218.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1453_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.canlet.2005.02.010","volume":"232","author":"YP Mei","year":"2006","unstructured":"Mei YP, Zhu XF, Zhou JM, Huang H, Deng R, Zeng YX. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Lett. 2006;232:189\u201398.","journal-title":"Cancer Lett"},{"key":"1453_CR11","first-page":"1363","volume":"13","author":"J Feng","year":"2023","unstructured":"Feng J, Zhang P, Yao P, Zhang H. EBNA2 mediates lipid metabolism and tumorigenesis through activation of ATF4 pathway. Am J Cancer Res. 2023;13:1363\u201376.","journal-title":"Am J Cancer Res"},{"key":"1453_CR12","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2008-11-190090","volume":"113","author":"H Kohlhof","year":"2009","unstructured":"Kohlhof H, Hampel F, Hoffmann R, Burtscher H, Weidle UH, H\u00f6lzel M, et al. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells. Blood. 2009;113:5506\u201315.","journal-title":"Blood"},{"key":"1453_CR13","doi-asserted-by":"publisher","first-page":"e1005339","DOI":"10.1371\/journal.ppat.1005339","volume":"12","author":"F Lu","year":"2016","unstructured":"Lu F, Chen HS, Kossenkov AV, DeWispeleare K, Won KJ, Lieberman PM. EBNA2 drives formation of new chromosome binding sites and target genes for B-cell master regulatory transcription factors RBP-j\u03ba and EBF1. PLoS Pathog. 2016;12:e1005339.","journal-title":"PLoS Pathog"},{"key":"1453_CR14","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.23.02366","volume":"42","author":"JK McGee-Avila","year":"2024","unstructured":"McGee-Avila JK, Suneja G, Engels EA, Rositch AF, Horner MJ, Luo Q, et al. Cancer treatment disparities in people with HIV in the United States, 2001-2019. J Clin Oncol. 2024;42:1810\u201320.","journal-title":"J Clin Oncol"},{"key":"1453_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","volume":"10","author":"Q Xiao","year":"2025","unstructured":"Xiao Q, Liu Y, Li T, Wang C, He S, Zhai L, et al. Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduct Target Ther. 2025;10:151.","journal-title":"Signal Transduct Target Ther"},{"key":"1453_CR16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1182\/bloodadvances.2020004058","volume":"5","author":"R Ramaswami","year":"2021","unstructured":"Ramaswami R, Lurain K, Polizzotto MN, Ekwede I, Waldon K, Steinberg SM, et al. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. Blood Adv. 2021;5:1660\u201370.","journal-title":"Blood Adv"},{"key":"1453_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bjh.18518","volume":"200","author":"T Zhou","year":"2023","unstructured":"Zhou T, Yuan CM, Lurain K, Rous C, Weaver L, Raffeld M, et al. A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions. Br J Haematol. 2023;200:462\u201375.","journal-title":"Br J Haematol"},{"key":"1453_CR18","doi-asserted-by":"publisher","first-page":"e1011703","DOI":"10.1371\/journal.ppat.1011703","volume":"19","author":"M Shimoda","year":"2023","unstructured":"Shimoda M, Inagaki T, Davis RR, Merleev A, Tepper CG, Maverakis E, et al. Virally encoded interleukin-6 facilitates KSHV replication in monocytes and induction of dysfunctional macrophages. PLoS Pathog. 2023;19:e1011703.","journal-title":"PLoS Pathog"},{"key":"1453_CR19","doi-asserted-by":"publisher","first-page":"50342","DOI":"10.18632\/oncotarget.17960","volume":"8","author":"DA Davis","year":"2017","unstructured":"Davis DA, Mishra S, Anagho HA, Aisabor AI, Shrestha P, Wang V, et al. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget. 2017;8:50342\u201358.","journal-title":"Oncotarget"},{"key":"1453_CR20","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2011-09-377705","volume":"119","author":"J Suthaus","year":"2012","unstructured":"Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, et al. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood. 2012;119:5173\u201381.","journal-title":"Blood"},{"key":"1453_CR21","doi-asserted-by":"crossref","unstructured":"Li Q, Xiang Q, Chen D, Nicholas J. Genetic analyses of contributions of viral interleukin-6 interactions and signaling to Human Herpesvirus 8 productive replication. J Virol. 2020;94:e00909\u201320.","DOI":"10.1128\/JVI.00909-20"},{"key":"1453_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/JVI.01192-15","volume":"90","author":"D Hu","year":"2016","unstructured":"Hu D, Wang V, Yang M, Abdullah S, Davis DA, Uldrick TS, et al. Induction of Kaposi\u2019s Sarcoma-associated Herpesvirus-encoded viral Interleukin-6 by X-Box binding protein 1. J Virol. 2016;90:368\u201378.","journal-title":"J Virol"},{"key":"1453_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/978-981-10-7230-7_16","volume":"1045","author":"H Katano","year":"2018","unstructured":"Katano H. Pathological features of Kaposi\u2019s sarcoma-associated herpesvirus infection. Adv Exp Med Biol. 2018;1045:357\u201376.","journal-title":"Adv Exp Med Biol"},{"key":"1453_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1143258","volume":"13","author":"V Svicher","year":"2023","unstructured":"Svicher V, Salpini R, D\u2019Anna S, Piermatteo L, Iannetta M, Malagnino V, et al. New insights into hepatitis B virus lymphotropism: Implications for HBV-related lymphomagenesis. Front Oncol. 2023;13:1143258.","journal-title":"Front Oncol"},{"key":"1453_CR25","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/kjm2.12283","volume":"36","author":"J Peng","year":"2020","unstructured":"Peng J, Li SJ, Fu X, Liu Y, Zhao XL. Chidamide acts on the histone deacetylase-mediated miR-34a\/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis. Kaohsiung J Med Sci. 2020;36:1004\u201313.","journal-title":"Kaohsiung J Med Sci"},{"key":"1453_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","volume":"51","author":"SN Meyer","year":"2019","unstructured":"Meyer SN, Scuoppo C, Vlasevska S, Bal E, Holmes AB, Holloman M, et al. Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B Cells reveal targetable dependencies in lymphoma. Immunity. 2019;51:535\u201347.e9.","journal-title":"Immunity"},{"key":"1453_CR27","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1038\/onc.2015.364","volume":"35","author":"B Dai","year":"2016","unstructured":"Dai B, Chen AY, Corkum CP, Peroutka RJ, Landon A, Houng S. Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders. Oncogene. 2016;35:2979\u201390.","journal-title":"Oncogene"},{"key":"1453_CR28","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1111\/cas.15097","volume":"112","author":"S Ito","year":"2021","unstructured":"Ito S, Iwanaga M, Nosaka K, Imaizumi Y, Ishitsuka K, Amano M, et al. Epidemiology of adult T-cell leukemia-lymphoma in Japan: an updated analysis, 2012-2013. Cancer Sci. 2021;112:4346\u201354.","journal-title":"Cancer Sci"},{"key":"1453_CR29","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1111\/febs.14492","volume":"285","author":"EW Harhaj","year":"2018","unstructured":"Harhaj EW, Giam CZ. NF-\u03baB signaling mechanisms in HTLV-1-induced adult T-cell leukemia\/lymphoma. FEBS J. 2018;285:3324\u201336.","journal-title":"FEBS J"},{"key":"1453_CR30","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/onc.2009.498","volume":"29","author":"YM Kim","year":"2010","unstructured":"Kim YM, Geiger TR, Egan DI, Sharma N, Nyborg JK. The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription. Oncogene. 2010;29:2142\u201352.","journal-title":"Oncogene"},{"key":"1453_CR31","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1128\/JVI.02460-09","volume":"84","author":"T Kinjo","year":"2010","unstructured":"Kinjo T, Ham-Terhune J, Peloponese JM Jr, Jeang KT. Induction of reactive oxygen species by human T-cell leukemia virus type 1 tax correlates with DNA damage and expression of cellular senescence marker. J Virol. 2010;84:5431\u20137.","journal-title":"J Virol"},{"key":"1453_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1375168","volume":"15","author":"R Su","year":"2024","unstructured":"Su R, Kang X, Niu Y, Zhao T, Wang H. PCBP1 interacts with the HTLV-1 Tax oncoprotein to potentiate NF-\u03baB activation. Front Immunol. 2024;15:1375168.","journal-title":"Front Immunol"},{"key":"1453_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00841-7","volume":"13","author":"R Hleihel","year":"2023","unstructured":"Hleihel R, Skayneh H, de Th\u00e9 H, Hermine O, Bazarbachi A. Primary cells from patients with adult T cell leukemia\/lymphoma depend on HTLV-1 Tax expression for NF-\u03baB activation and survival. Blood Cancer J. 2023;13:67.","journal-title":"Blood Cancer J"},{"key":"1453_CR34","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.V98.4.1200","volume":"98","author":"T Portis","year":"2001","unstructured":"Portis T, Harding JC, Ratner L. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood. 2001;98:1200\u20138.","journal-title":"Blood"},{"key":"1453_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s42003-022-04284-x","volume":"5","author":"T Kameda","year":"2022","unstructured":"Kameda T, Shide K, Kamiunten A, Kogure Y, Morishita D, Koya J, et al. CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia\/lymphoma. Commun Biol. 2022;5:1309.","journal-title":"Commun Biol"},{"key":"1453_CR36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","volume":"129","author":"T Watanabe","year":"2017","unstructured":"Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017;129:1071\u201381.","journal-title":"Blood"},{"key":"1453_CR37","doi-asserted-by":"crossref","unstructured":"Eslami M, Arjmand N, Mahmoudian F, Babaeizad A, Tahmasebi H, Fattahi F, et al. Deciphering host-virus interactions and advancing therapeutics for chronic viral infection. Viruses 2025;17:390.","DOI":"10.3390\/v17030390"},{"key":"1453_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05288-0","volume":"9","author":"X Zhao","year":"2018","unstructured":"Zhao X, Sankaran S, Yap J, Too CT, Ho ZZ, Dolton G, et al. Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling. Nat Commun. 2018;9:2716.","journal-title":"Nat Commun"},{"key":"1453_CR39","doi-asserted-by":"publisher","first-page":"6148","DOI":"10.1182\/blood-2009-02-203687","volume":"113","author":"C Smith","year":"2009","unstructured":"Smith C, Wakisaka N, Crough T, Peet J, Yoshizaki T, Beagley L, et al. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood. 2009;113:6148\u201352.","journal-title":"Blood"},{"key":"1453_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/13550280490521104","volume":"10","author":"K Mostoller","year":"2004","unstructured":"Mostoller K, Norbury CC, Jain P, Wigdahl B. Human T-cell leukemia virus type I Tax induces the expression of dendritic cell markers associated with maturation and activation. J Neurovirol. 2004;10:358\u201371.","journal-title":"J Neurovirol"},{"key":"1453_CR41","doi-asserted-by":"crossref","unstructured":"Schnell AP, Kohrt S, Thoma-Kress AK. Latency reversing agents: kick and kill of HTLV-1? Int J Mol Sci. 2021;22:5545.","DOI":"10.3390\/ijms22115545"},{"key":"1453_CR42","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1182\/blood-2010-06-288035","volume":"117","author":"D Favre","year":"2011","unstructured":"Favre D, Stoddart CA, Emu B, Hoh R, Martin JN, Hecht FM, et al. HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood. 2011;117:2189\u201399.","journal-title":"Blood"},{"key":"1453_CR43","doi-asserted-by":"publisher","first-page":"10903","DOI":"10.2147\/OTT.S217767","volume":"12","author":"H Dan","year":"2019","unstructured":"Dan H, Zhang S, Zhou Y, Guan QDNA. Methyltransferase inhibitors: catalysts for antitumour immune responses. Onco Targets Ther. 2019;12:10903\u201316.","journal-title":"Onco Targets Ther"},{"key":"1453_CR44","doi-asserted-by":"crossref","unstructured":"Ren J, Li N, Pei S, Lian Y, Li L, Peng Y, et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-\u03b3-stimulated antitumor immunity. J Clin Invest. 2022;132:e153167.","DOI":"10.1172\/JCI153167"},{"key":"1453_CR45","doi-asserted-by":"crossref","unstructured":"Zhang T, Beytullahoglu O, Tulaiha R, Luvisotto A, Szczepanski A, Tsuboyama N, et al. An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models. J Clin Invest. 2025;35:e179703.","DOI":"10.1172\/JCI179703"},{"key":"1453_CR46","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-023-01438-z","volume":"8","author":"SY Zhang","year":"2023","unstructured":"Zhang SY, Xu QP, Shi LN, Li SW, Wang WH, Wang QQ, et al. Soluble CD4 effectively prevents excessive TLR activation of resident macrophages in the onset of sepsis. Signal Transduct Target Ther. 2023;8:236.","journal-title":"Signal Transduct Target Ther"},{"key":"1453_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24\u201333.","journal-title":"Trends Mol Med"},{"key":"1453_CR48","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/cac2.12587","volume":"44","author":"W Sun","year":"2024","unstructured":"Sun W, Hu S, Wang X. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies. Cancer Commun. 2024;44:1071\u201397.","journal-title":"Cancer Commun"},{"key":"1453_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118515","volume":"191","author":"L Qi","year":"2025","unstructured":"Qi L, Hu B, Cao C, Peng T, Xu M, Liu S, et al. Viral oncogenesis and immune remodeling: decoding the therapeutic potential of immune checkpoint inhibitors in virus-associated cancers. Biomed Pharmacother. 2025;191:118515.","journal-title":"Biomed Pharmacother"},{"key":"1453_CR50","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/QAD.0000000000001713","volume":"32","author":"C Domblides","year":"2018","unstructured":"Domblides C, Antoine M, Hamard C, Rabbe N, Rodenas A, Vieira T, et al. Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. AIDS. 2018;32:461\u20138.","journal-title":"AIDS"},{"key":"1453_CR51","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41423-018-0021-3","volume":"16","author":"X Zhang","year":"2019","unstructured":"Zhang X, Cheng C, Hou J, Qi X, Wang X, Han P, et al. Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells. Cell Mol Immunol. 2019;16:392\u2013400.","journal-title":"Cell Mol Immunol"},{"key":"1453_CR52","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin B, Adam S, Cassini MF, Sanchez G, Liria M, Aykut B, et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol. 2020;21:442\u201354.","journal-title":"Nat Immunol"},{"key":"1453_CR53","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1756-8722-6-74","volume":"6","author":"L Shi","year":"2013","unstructured":"Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74.","journal-title":"J Hematol Oncol"},{"key":"1453_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1265299","volume":"14","author":"H Cao","year":"2023","unstructured":"Cao H, Wu T, Zhou X, Xie S, Sun H, Sun Y, et al. Progress of research on PD-1\/PD-L1 in leukemia. Front Immunol. 2023;14:1265299.","journal-title":"Front Immunol"},{"key":"1453_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105999","volume":"77","author":"M Xie","year":"2019","unstructured":"Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol. 2019;77:105999.","journal-title":"Int Immunopharmacol"},{"key":"1453_CR56","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1089\/aid.2012.0320","volume":"29","author":"AC Sherman","year":"2013","unstructured":"Sherman AC, Trehanpati N, Daucher M, Davey RT, Masur H, Sarin SK, et al. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1\/programmed death receptor-L1 blockade in hepatitis B virus and HIV\/hepatitis B virus coinfected patients treated with adefovir. AIDS Res Hum Retroviruses. 2013;29:665\u201372.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"1453_CR57","first-page":"765","volume":"24","author":"CY-F Wei Zheng","year":"2014","unstructured":"Wei Zheng CY-F, Wang Z-M, Zou S-H. The impact of hepatitis B virus concurrent infection on peripheral T cells in diffuse large B-cell lymphoma patients. China Oncol. 2014;24:765\u20139.","journal-title":"China Oncol"},{"key":"1453_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1216610","volume":"14","author":"X Wan","year":"2023","unstructured":"Wan X, Young KH, Bai O. HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy. Front Immunol. 2023;14:1216610.","journal-title":"Front Immunol"},{"key":"1453_CR59","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1182\/blood-2017-11-817601","volume":"131","author":"W Ren","year":"2018","unstructured":"Ren W, Ye X, Su H, Li W, Liu D, Pirmoradian M, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018;131:2670\u201381.","journal-title":"Blood"},{"key":"1453_CR60","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1073\/pnas.1701836114","volume":"114","author":"T Minamitani","year":"2017","unstructured":"Minamitani T, Ma Y, Zhou H, Kida H, Tsai CY, Obana M, et al. Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease. Proc Natl Acad Sci USA. 2017;114:4751\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1453_CR61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.virol.2021.02.004","volume":"557","author":"Y Yanagi","year":"2021","unstructured":"Yanagi Y, Okuno Y, Narita Y, Masud HMAA, Watanabe T, Sato Y, et al. RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. Virology. 2021;557:44\u201354.","journal-title":"Virology"},{"key":"1453_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12038-015-9502-z","volume":"40","author":"TB Mohidin","year":"2015","unstructured":"Mohidin TB, Ng CC. BARF1 gene silencing triggers caspase-dependent mitochondrial apoptosis in Epstein-Barr virus-positive malignant cells. J Biosci. 2015;40:41\u201351.","journal-title":"J Biosci"},{"key":"1453_CR63","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4049\/jimmunol.2300599","volume":"212","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wei X, Zhang Q, Jiao X, Li K, Geng M, et al. Fish uses CTLA-4 immune checkpoint to suppress mTORC1-controlled T-cell glycolysis and immunity. J Immunol. 2024;212:1113\u201328.","journal-title":"J Immunol"},{"key":"1453_CR64","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1515\/biol-2021-0094","volume":"16","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li M, Cao J, et al. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression. Open Life Sci. 2021;16:909\u201319.","journal-title":"Open Life Sci"},{"key":"1453_CR65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1084\/jem.189.2.435","volume":"189","author":"DA Mandelbrot","year":"1999","unstructured":"Mandelbrot DA, McAdam AJ, Sharpe AH. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med. 1999;189:435\u201340.","journal-title":"J Exp Med"},{"key":"1453_CR66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13046-023-02691-4","volume":"42","author":"K Okuyama","year":"2023","unstructured":"Okuyama K, Naruse T, Yanamoto S. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2023;42:114.","journal-title":"J Exp Clin Cancer Res"},{"key":"1453_CR67","doi-asserted-by":"crossref","unstructured":"Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, et al. Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4. J Immunother Cancer. 2020;8:e000764.","DOI":"10.1136\/jitc-2020-000764"},{"key":"1453_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100886","volume":"65","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zheng N, Li J, Li C, Zheng D, Jiang X, et al. N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells. Drug Resist Updat. 2022;65:100886.","journal-title":"Drug Resist Updat"},{"key":"1453_CR69","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.3389\/fimmu.2018.02755","volume":"9","author":"K Yasuma-Mitobe","year":"2018","unstructured":"Yasuma-Mitobe K, Matsuoka M. The roles of coinhibitory receptors in pathogenesis of human retroviral infections. Front Immunol. 2018;9:2755.","journal-title":"Front Immunol"},{"key":"1453_CR70","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00369","volume":"9","author":"B Valcarcel","year":"2023","unstructured":"Valcarcel B, Enriquez-Vera D, De-la-Cruz-Ku G, Chambergo-Michilot D, Calder\u00f3n-Huaycochea H, Malpica L. Epidemiological features and outcomes of HTLV-1 carriers diagnosed with cancer: a retrospective cohort study in an endemic country. JCO Glob Oncol. 2023;9:e2200369.","journal-title":"JCO Glob Oncol"},{"key":"1453_CR71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.imlet.2021.09.009","volume":"240","author":"F Esen","year":"2021","unstructured":"Esen F, Deniz G, Aktas EC. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions. Immunol Lett. 2021;240:15\u201323.","journal-title":"Immunol Lett"},{"key":"1453_CR72","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/2040620716673787","volume":"8","author":"N Galanina","year":"2017","unstructured":"Galanina N, Kline J, Bishop MR. Emerging role of checkpoint blockade therapy in lymphoma. Ther Adv Hematol. 2017;8:81\u201390.","journal-title":"Ther Adv Hematol"},{"key":"1453_CR73","doi-asserted-by":"crossref","unstructured":"Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers 2021;13:1440.","DOI":"10.3390\/cancers13061440"},{"key":"1453_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103085","volume":"21","author":"S Gertel","year":"2022","unstructured":"Gertel S, Polachek A, Elkayam O, Furer V. Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases. Autoimmun Rev. 2022;21:103085.","journal-title":"Autoimmun Rev"},{"key":"1453_CR75","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.cell.2025.06.004","volume":"188","author":"J Du","year":"2025","unstructured":"Du J, Chen H, You J, Hu W, Liu J, Lu Q, et al. Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity. Cell. 2025;188:4025\u201342.e20.","journal-title":"Cell"},{"key":"1453_CR76","doi-asserted-by":"publisher","first-page":"e012747","DOI":"10.1136\/jitc-2025-012747","volume":"13","author":"GV Stephen Hodi","year":"2025","unstructured":"Stephen Hodi GV, Tawbi F, Schadendorf H. D. Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. J Immunother Cancer. 2025;13:e012747.","journal-title":"J Immunother Cancer"},{"key":"1453_CR77","doi-asserted-by":"publisher","first-page":"6540","DOI":"10.1182\/blood-2022-166846","volume":"140","author":"NA Johnson","year":"2022","unstructured":"Johnson NA, Lavie D, Borchmann P, Gregory GP, Herrera AF, Minuk L, et al. Updated results from an open-label phase 1\/2 study of favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma. Blood. 2022;140:6540\u20132.","journal-title":"Blood"},{"key":"1453_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112516","volume":"146","author":"H Alemohammad","year":"2022","unstructured":"Alemohammad H, Najafzadeh B, Asadzadeh Z, Baghbanzadeh A, Ghorbaninezhad F, Najafzadeh A, et al. The importance of immune checkpoints in immune monitoring: a future paradigm shift in the treatment of cancer. Biomed Pharmacother. 2022;146:112516.","journal-title":"Biomed Pharmacother"},{"key":"1453_CR79","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11912-022-01218-y","volume":"24","author":"AL Gomes de Morais","year":"2022","unstructured":"Gomes de Morais AL, Cerd\u00e1 S, de Miguel M. New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors. Curr Oncol Rep. 2022;24:651\u20138.","journal-title":"Curr Oncol Rep"},{"key":"1453_CR80","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40123-024-00913-2","volume":"13","author":"J Wang","year":"2024","unstructured":"Wang J, Li Z, Yin H. The future of checkpoint inhibitors in uveal melanoma: a narrative review. Ophthalmol Ther. 2024;13:1103\u201323.","journal-title":"Ophthalmol Ther"},{"key":"1453_CR81","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","volume":"10","author":"CY Ok","year":"2017","unstructured":"Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017;10:103.","journal-title":"J Hematol Oncol"},{"key":"1453_CR82","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1172\/JCI57175","volume":"123","author":"A Chaudhry","year":"2013","unstructured":"Chaudhry A, Rudensky AY. Control of inflammation by integration of environmental cues by regulatory T cells. J Clin Invest. 2013;123:939\u201344.","journal-title":"J Clin Invest"},{"key":"1453_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943354","volume":"13","author":"K Maharaj","year":"2022","unstructured":"Maharaj K, Uriepero A, Sahakian E, Pinilla-Ibarz J. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. Front Immunol. 2022;13:943354.","journal-title":"Front Immunol"},{"key":"1453_CR84","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.acr.2019.05.001","volume":"144","author":"A Toker","year":"2019","unstructured":"Toker A, Ohashi PS. Expression of costimulatory and inhibitory receptors in FoxP3(+) regulatory T cells within the tumor microenvironment: implications for combination immunotherapy approaches. Adv Cancer Res. 2019;144:193\u2013261.","journal-title":"Adv Cancer Res"},{"key":"1453_CR85","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00432-020-03398-1","volume":"146","author":"F Peng","year":"2020","unstructured":"Peng F, Qin Y, Mu S, Li J, Ai L, Hu Y. Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020;146:3123\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1453_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63494-x","volume":"14","author":"Y Egawa","year":"2024","unstructured":"Egawa Y, Higuchi T, Hashida Y, Ueno K, Kojima K, Daibata M. Novel paired CD13-negative (MT-50.1) and CD13-positive (MT-50.4) HTLV-1-infected T-cell lines with differential regulatory T cell-like activity. Sci Rep. 2024;14:12549.","journal-title":"Sci Rep"},{"key":"1453_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107680","volume":"152","author":"T Shichijo","year":"2025","unstructured":"Shichijo T, Yasunaga JI. Stratagems of HTLV-1 for persistent infection and the resultant oncogenesis: Immune evasion and clonal expansion. Leuk Res. 2025;152:107680.","journal-title":"Leuk Res"},{"key":"1453_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70171","volume":"9","author":"AAM Alkhdir","year":"2025","unstructured":"Alkhdir AAM, Mohamedsharif AA, Mohammed IBS, Abbas AM. Seroprevalence and risk factors of hepatitis B virus among newly diagnosed cancer patients in Khartoum state: implications for chemotherapy management and screening protocols. JGH Open. 2025;9:e70171.","journal-title":"JGH Open"},{"key":"1453_CR89","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.canlet.2019.03.040","volume":"452","author":"D Wang","year":"2019","unstructured":"Wang D, Yang L, Yue D, Cao L, Li L, Wang D, et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. Cancer Lett. 2019;452:244\u201353.","journal-title":"Cancer Lett"},{"key":"1453_CR90","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","volume":"36","author":"CM Bollard","year":"2018","unstructured":"Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma. J Clin Oncol. 2018;36:1128\u201339.","journal-title":"J Clin Oncol"},{"key":"1453_CR91","doi-asserted-by":"crossref","unstructured":"Betzler AC, Theodoraki MN, Schuler PJ, D\u00f6scher J, Laban S, Hoffmann TK, et al. NF-\u03baB and its role in checkpoint control. Int J Mol Sci. 2020;21:3949.","DOI":"10.3390\/ijms21113949"},{"key":"1453_CR92","doi-asserted-by":"publisher","first-page":"9680","DOI":"10.1128\/JVI.01001-07","volume":"81","author":"BA Mainou","year":"2007","unstructured":"Mainou BA, Everly DN Jr, Raab-Traub N. Unique signaling properties of CTAR1 in LMP1-mediated transformation. J Virol. 2007;81:9680\u201392.","journal-title":"J Virol"},{"key":"1453_CR93","doi-asserted-by":"publisher","first-page":"e63566","DOI":"10.1371\/journal.pone.0063566","volume":"8","author":"T Murata","year":"2013","unstructured":"Murata T, Iwata S, Siddiquey MN, Kanazawa T, Goshima F, Kawashima D, et al. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PLoS ONE. 2013;8:e63566.","journal-title":"PLoS ONE"},{"key":"1453_CR94","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.virol.2023.02.012","volume":"581","author":"SB York","year":"2023","unstructured":"York SB, Hurwitz SN, Liu X, Meckes DG Jr. Ceramide-dependent trafficking of Epstein-Barr virus LMP1 to small extracellular vesicles. Virology. 2023;581:128\u201338.","journal-title":"Virology"},{"key":"1453_CR95","doi-asserted-by":"publisher","first-page":"S326","DOI":"10.1007\/s12032-010-9681-2","volume":"28","author":"X Ke","year":"2011","unstructured":"Ke X, Yang YC, Hong SL. EBV-LMP1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666-1 xenograft model. Med Oncol. 2011;28:S326\u201332.","journal-title":"Med Oncol"},{"key":"1453_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39732-y","volume":"9","author":"N Ammous-Boukhris","year":"2019","unstructured":"Ammous-Boukhris N, Mosbah A, Ayadi W, Sahli E, Chevance S, Bondon A, et al. B1.12: a novel peptide interacting with the extracellular loop of the EBV oncoprotein LMP1. Sci Rep. 2019;9:4389.","journal-title":"Sci Rep"},{"key":"1453_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70407","volume":"97","author":"G Zarkovic","year":"2025","unstructured":"Zarkovic G, Ziegler P, Lee JH, et al. Disruption of ATR signaling by Epstein-Barr virus latent membrane protein 1 sensitizes nasopharyngeal carcinoma cells to cisplatin. J Med Virol. 2025;97:e70407.","journal-title":"J Med Virol"},{"key":"1453_CR98","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y","volume":"68","author":"AK Chiang","year":"1996","unstructured":"Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin\u2019s disease. Int J Cancer. 1996;68:285\u201390.","journal-title":"Int J Cancer"},{"key":"1453_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.102","volume":"47","author":"E Tse","year":"2015","unstructured":"Tse E, Kwong YL. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med. 2015;47:e136.","journal-title":"Exp Mol Med"},{"key":"1453_CR100","doi-asserted-by":"crossref","unstructured":"Messick TE, Tolvinski L, Zartler ER, Moberg A, Frostell \u00c5, Smith GR, et al. Biophysical screens identify fragments that bind to the viral DNA-binding proteins EBNA1 and LANA. Molecules 2020;25:1760.","DOI":"10.3390\/molecules25071760"},{"key":"1453_CR101","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1021\/acsami.4c20023","volume":"17","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Wen Y, Xie Y, Chen G, Hu S, Wu Y, et al. Intelligent hierarchical targeting near-infrared persistent luminescence nanosystem for improved nuclear delivery and simultaneous visualization\/therapy of EBV-associated cancer. ACS Appl Mater Interfaces. 2025;17:3072\u201383.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1453_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5775","volume":"38","author":"MT Davis","year":"2024","unstructured":"Davis MT, Anders NM, Colevas AD, Messick TE, Rudek MA. Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor. Biomed Chromatogr. 2024;38:e5775.","journal-title":"Biomed Chromatogr"},{"key":"1453_CR103","doi-asserted-by":"publisher","first-page":"e1005344","DOI":"10.1371\/journal.ppat.1005344","volume":"11","author":"X Lin","year":"2015","unstructured":"Lin X, Tsai MH, Shumilov A, Poirey R, Bannert H, Middeldorp JM, et al. The Epstein-Barr virus BART miRNA cluster of the M81 strain modulates multiple functions in primary B cells. PLoS Pathog. 2015;11:e1005344.","journal-title":"PLoS Pathog"},{"key":"1453_CR104","doi-asserted-by":"publisher","first-page":"999","DOI":"10.32604\/or.2024.046679","volume":"32","author":"X Zhao","year":"2024","unstructured":"Zhao X, Huang X, Dang C, Wang X, Qi Y, Li H. The Epstein-Barr virus-miRNA-BART6-5p regulates TGF-\u03b2\/SMAD4 pathway to induce glycolysis and enhance proliferation and metastasis of gastric cancer cells. Oncol Res. 2024;32:999\u20131009.","journal-title":"Oncol Res"},{"key":"1453_CR105","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00572-24","volume":"98","author":"GH Willman","year":"2024","unstructured":"Willman GH, Xu H, Zeigler TM, McIntosh MT, Bhaduri-McIntosh S. Polymerase theta is a synthetic lethal target for killing Epstein-Barr virus lymphomas. J Virol. 2024;98:e0057224.","journal-title":"J Virol"},{"key":"1453_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-020-00538-w","volume":"17","author":"S Millen","year":"2020","unstructured":"Millen S, Meretuk L, G\u00f6ttlicher T, Schmitt S, Fleckenstein B, Thoma-Kress AK. A novel positive feedback-loop between the HTLV-1 oncoprotein Tax and NF-\u03baB activity in T-cells. Retrovirology. 2020;17:30.","journal-title":"Retrovirology"},{"key":"1453_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978800","volume":"13","author":"AP Schnell","year":"2022","unstructured":"Schnell AP, Kohrt S, Aristodemou A, Taylor GP, Bangham CRM, Thoma-Kress AK. HDAC inhibitors Panobinostat and Romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients\u2019 T-cells. Front Immunol. 2022;13:978800.","journal-title":"Front Immunol"},{"key":"1453_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117584","volume":"180","author":"SH Zhang","year":"2024","unstructured":"Zhang SH, Zeng N, Xu JZ, Liu CQ, Xu MY, Sun JX, et al. Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs. Biomed Pharmacother. 2024;180:117584.","journal-title":"Biomed Pharmacother"},{"key":"1453_CR109","doi-asserted-by":"publisher","first-page":"468","DOI":"10.7555\/JBR.28.20140066","volume":"28","author":"X Tang","year":"2014","unstructured":"Tang X, Zhou Y, Li W, Tang Q, Chen R, Zhu J, et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res. 2014;28:468\u201375.","journal-title":"J Biomed Res"},{"key":"1453_CR110","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","volume":"29","author":"J Ruan","year":"2011","unstructured":"Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:690\u20137.","journal-title":"J Clin Oncol"},{"key":"1453_CR111","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.23.00033","volume":"41","author":"AJ Davies","year":"2023","unstructured":"Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, et al. Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up. J Clin Oncol. 2023;41:2718\u201323.","journal-title":"J Clin Oncol"},{"key":"1453_CR112","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1182\/blood-2014-04-572750","volume":"125","author":"Z Dassouki","year":"2015","unstructured":"Dassouki Z, Sahin U, El Hajj H, Jollivet F, Kfoury Y, Lallemand-Breitenbach V, et al. ATL response to arsenic\/interferon therapy is triggered by SUMO\/PML\/RNF4-dependent Tax degradation. Blood. 2015;125:474\u201382.","journal-title":"Blood"},{"key":"1453_CR113","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13000-024-01552-8","volume":"19","author":"VK Vetter","year":"2024","unstructured":"Vetter VK, Haberecker M, Huber FA, Pauli C. Aberrant positivity for BCOR immunohistochemistry in merkel cell carcinoma - a potential diagnostic pitfall. Diagn Pathol. 2024;19:130.","journal-title":"Diagn Pathol"},{"key":"1453_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216618","volume":"584","author":"N Weng","year":"2024","unstructured":"Weng N, Zhou C, Zhou Y, Zhong Y, Jia Z, Rao X, et al. IKZF4\/NONO-RAB11FIP3 axis promotes immune evasion in gastric cancer via facilitating PD-L1 endosome recycling. Cancer Lett. 2024;584:216618.","journal-title":"Cancer Lett"},{"key":"1453_CR115","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14:203\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"1453_CR116","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1002\/cam4.4198","volume":"10","author":"A Satou","year":"2021","unstructured":"Satou A, Nakamura S. EBV-positive B-cell lymphomas and lymphoproliferative disorders: review from the perspective of immune escape and immunodeficiency. Cancer Med. 2021;10:6777\u201385.","journal-title":"Cancer Med"},{"key":"1453_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.785153","volume":"12","author":"X Cai","year":"2021","unstructured":"Cai X, Zhan H, Ye Y, Yang J, Zhang M, Li J, et al. Current progress and future perspectives of immune checkpoint in cancer and infectious diseases. Front Genet. 2021;12:785153.","journal-title":"Front Genet"},{"key":"1453_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28479-2","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Ge J, Wang Y, Xiong F, Guo J, Jiang X, et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nat Commun. 2022;13:866.","journal-title":"Nat Commun"},{"key":"1453_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982026","volume":"13","author":"L Yu","year":"2022","unstructured":"Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: providing new hope for oncotherapy. Front Immunol. 2022;13:982026.","journal-title":"Front Immunol"},{"key":"1453_CR120","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462\u201373.","journal-title":"Clin Cancer Res"},{"key":"1453_CR121","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126:2193\u2013201.","journal-title":"Blood"},{"key":"1453_CR122","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O\u2019Donnell E, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18:1611\u20138.","journal-title":"Clin Cancer Res"},{"key":"1453_CR123","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698\u2013704.","journal-title":"J Clin Oncol"},{"key":"1453_CR124","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/bjh.16494","volume":"189","author":"SD Smith","year":"2020","unstructured":"Smith SD, Till BG, Shadman MS, Lynch RC, Cowan AJ, Wu QV, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020;189:1119\u201326.","journal-title":"Br J Haematol"},{"key":"1453_CR125","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1182\/bloodadvances.2022008344","volume":"7","author":"A Younes","year":"2023","unstructured":"Younes A, Burke JM, Cheson BD, Diefenbach CS, Ferrari S, Hahn UH, et al. Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. Blood Adv. 2023;7:1488\u201395.","journal-title":"Blood Adv"},{"key":"1453_CR126","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","volume":"13","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Martelli M, Trn\u011bn\u00fd M, Liu W, Bolen CR, Knapp A, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13:71.","journal-title":"J Hematol Oncol"},{"key":"1453_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02515-5","volume":"12","author":"Y Feng","year":"2022","unstructured":"Feng Y, Feng X, Jing C, Yu X, Zheng Y, Xu C. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK\/T cell lymphoma. Sci Rep. 2022;12:36.","journal-title":"Sci Rep"},{"key":"1453_CR128","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J Hematol Oncol. 2016;9:109.","journal-title":"J Hematol Oncol"},{"key":"1453_CR129","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3324\/haematol.2017.180430","volume":"103","author":"SB Ng","year":"2018","unstructured":"Ng SB, Chung TH, Kato S, Nakamura S, Takahashi E, Ko YH, et al. Epstein-Barr virus-associated primary nodal T\/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica. 2018;103:278\u201387.","journal-title":"Haematologica"},{"key":"1453_CR130","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","volume":"66","author":"T Nagato","year":"2017","unstructured":"Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017;66:877\u201390.","journal-title":"Cancer Immunol Immunother"},{"key":"1453_CR131","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","volume":"6","author":"R Tao","year":"2021","unstructured":"Tao R, Fan L, Song Y, Hu Y, Zhang W, Wang Y, et al. Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther. 2021;6:365.","journal-title":"Signal Transduct Target Ther"},{"key":"1453_CR132","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood. 2017;129:2437\u201342.","journal-title":"Blood"},{"key":"1453_CR133","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-023-01483-9","volume":"16","author":"XP Tian","year":"2023","unstructured":"Tian XP, Cao Y, Cai J, Zhang YC, Zou QH, Wang JN, et al. Novel target and treatment agents for natural killer\/T-cell lymphoma. J Hematol Oncol. 2023;16:78.","journal-title":"J Hematol Oncol"},{"key":"1453_CR134","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","volume":"9","author":"Y Gao","year":"2024","unstructured":"Gao Y, He H, Li X, Zhang L, Xu W, Feng R, et al. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib\/II study. Signal Transduct Target Ther. 2024;9:121.","journal-title":"Signal Transduct Target Ther"},{"key":"1453_CR135","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1158\/0008-5472.CAN-17-2176","volume":"78","author":"L Meder","year":"2018","unstructured":"Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, et al. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res. 2018;78:4270\u201381.","journal-title":"Cancer Res"},{"key":"1453_CR136","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood.2023021423","volume":"143","author":"M Chiba","year":"2024","unstructured":"Chiba M, Shimono J, Suto K, Ishio T, Endo T, Goto H, et al. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia\/lymphoma. Blood. 2024;143:1379\u201390.","journal-title":"Blood"},{"key":"1453_CR137","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/leu.2008.272","volume":"23","author":"T Kozako","year":"2009","unstructured":"Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, et al. PD-1\/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia\/lymphoma patients. Leukemia. 2009;23:375\u201382.","journal-title":"Leukemia"},{"key":"1453_CR138","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","volume":"128","author":"H Miyoshi","year":"2016","unstructured":"Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma. Blood. 2016;128:1374\u201381.","journal-title":"Blood"},{"key":"1453_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.140","volume":"3","author":"J Liu","year":"2022","unstructured":"Liu J, Zhang F, Yu J, Zhao Q. Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential. MedComm. 2022;3:e140.","journal-title":"MedComm"},{"key":"1453_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107870","volume":"98","author":"M Jalili-Nik","year":"2021","unstructured":"Jalili-Nik M, Soltani A, Mashkani B, Rafatpanah H, Hashemy SI. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia\/Lymphoma. Int Immunopharmacol. 2021;98:107870.","journal-title":"Int Immunopharmacol"},{"key":"1453_CR141","doi-asserted-by":"crossref","unstructured":"Ko B, Takebe N, Andrews O, Makena MR, Chen AP. Rethinking oncologic treatment strategies with interleukin-2. Cells 2023;12:1316.","DOI":"10.3390\/cells12091316"},{"key":"1453_CR142","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.clml.2024.03.011","volume":"24","author":"K Lurain","year":"2024","unstructured":"Lurain K, Zarif TE, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, et al. Real-world multicenter study of PD-1 blockade in HIV-associated classical hodgkin lymphoma across the United States. Clin Lymphoma Myeloma Leuk. 2024;24:523\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1453_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100965","volume":"55","author":"X Chen","year":"2022","unstructured":"Chen X, Jia L, Zhang X, Zhang T, Zhang Y. One arrow for two targets: potential co-treatment regimens for lymphoma and HIV. Blood Rev. 2022;55:100965.","journal-title":"Blood Rev"},{"key":"1453_CR144","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","volume":"5","author":"TS Uldrick","year":"2019","unstructured":"Uldrick TS, Gon\u00e7alves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study. JAMA Oncol. 2019;5:1332\u20139.","journal-title":"JAMA Oncol"},{"key":"1453_CR145","doi-asserted-by":"crossref","unstructured":"Host KM, Jacobs SR, West JA, Zhang Z, Costantini LM, Stopford CM, et al. Kaposi\u2019s sarcoma-associated herpesvirus increases PD-L1 and proinflammatory cytokine expression in human monocytes. mBio 2017;8:e00917\u201317.","DOI":"10.1128\/mBio.00917-17"},{"key":"1453_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.574752","volume":"10","author":"X Li","year":"2020","unstructured":"Li X, Yan S, Yang J, Wang Y, Lv C, Li S, et al. Efficacy and Safety of PD-1\/PD-L1 inhibitors plus chemotherapy versus PD-1\/PD-L1 inhibitors in advanced non-small cell lung cancer: a network analysis of randomized controlled trials. Front Oncol. 2020;10:574752.","journal-title":"Front Oncol"},{"key":"1453_CR147","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.tibs.2018.09.004","volume":"43","author":"J Zhang","year":"2018","unstructured":"Zhang J, Dang F, Ren J, Wei W. Biochemical aspects of PD-L1 regulation in cancer immunotherapy. Trends Biochem Sci. 2018;43:1014\u201332.","journal-title":"Trends Biochem Sci"},{"key":"1453_CR148","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-017-0479-y","volume":"10","author":"D Liu","year":"2017","unstructured":"Liu D, Wang S, Bindeman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol. 2017;10:110.","journal-title":"J Hematol Oncol"},{"key":"1453_CR149","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00432-022-04286-6","volume":"149","author":"D Wankhede","year":"2023","unstructured":"Wankhede D, Hofman P, Grover S. PD-1\/PD-L1 inhibitors in treatment-na\u00efve, advanced non-small cell lung cancer patients with<1% PD-L1 expression: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2023;149:2179\u201389.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1453_CR150","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3389\/fimmu.2020.01037","volume":"11","author":"B Li","year":"2020","unstructured":"Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, et al. Anti-PD-1\/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review. Front Immunol. 2020;11:1037.","journal-title":"Front Immunol"},{"key":"1453_CR151","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/ajco.13959","volume":"20","author":"SH Lim","year":"2024","unstructured":"Lim SH, Choi SH, Ji YS, Kim SH, Kim CK, Yun J, et al. Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. Asia Pac J Clin Oncol. 2024;20:346\u201353.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1453_CR152","doi-asserted-by":"publisher","first-page":"e0180390","DOI":"10.1371\/journal.pone.0180390","volume":"12","author":"Z Liu","year":"2017","unstructured":"Liu Z, Li S, Liu Y, Guo W, Bai O. PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection. PLoS ONE. 2017;12:e0180390.","journal-title":"PLoS ONE"},{"key":"1453_CR153","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1464-410X.1990.tb14841.x","volume":"65","author":"A G\u00fcrsan","year":"1990","unstructured":"G\u00fcrsan A, Egilmez AN. Unilateral intra-abdominal testis with seminoma in a previously unrecognised hermaphrodite. Br J Urol. 1990;65:654\u20135.","journal-title":"Br J Urol"},{"key":"1453_CR154","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcaf017","volume":"7","author":"H Xu","year":"2025","unstructured":"Xu H, Hutchinson TE, Koganti S, Rousseau BA, Xia D, McIntosh MT, et al. Leveraging the interconnected unfolded protein response and NLRP3 inflammasome pathways to reactivate Epstein-Barr virus in diffuse large B-cell lymphomas. NAR Cancer. 2025;7:zcaf017.","journal-title":"NAR Cancer"},{"key":"1453_CR155","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1172\/JCI125364","volume":"129","author":"J R\u00fchl","year":"2019","unstructured":"R\u00fchl J, Citterio C, Engelmann C, Haigh T, Dzionek A, Dreyer J, et al. Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas. J Clin Invest. 2019;129:2071\u201387.","journal-title":"J Clin Invest"},{"key":"1453_CR156","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/01.HYP.9.2.132","volume":"9","author":"S Laurent","year":"1987","unstructured":"Laurent S, Girerd X, Tsoukaris-Kupfer D, Legrand M, Huchet-Brisac AM, Schmitt H. Opposite central cardiovascular effects of nifedipine and BAY k 8644 in anesthetized rats. Hypertension. 1987;9:132\u20138.","journal-title":"Hypertension"},{"key":"1453_CR157","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/OV.S145532","volume":"7","author":"CY Chen","year":"2018","unstructured":"Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1\/PD-L1 blockade combination therapy. Oncolytic Virother. 2018;7:65\u201377.","journal-title":"Oncolytic Virother"},{"key":"1453_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02503-8","volume":"7","author":"CY Chen","year":"2017","unstructured":"Chen CY, Wang PY, Hutzen B, Sprague L, Swain HM, Love JK, et al. Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models. Sci Rep. 2017;7:2396.","journal-title":"Sci Rep"},{"key":"1453_CR159","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:2619\u201326.","journal-title":"J Clin Oncol"},{"key":"1453_CR160","first-page":"493","volume":"19","author":"J Hardcastle","year":"2017","unstructured":"Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, et al. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro-Oncology. 2017;19:493\u2013502.","journal-title":"Neuro-Oncology"},{"key":"1453_CR161","first-page":"1016","volume":"45","author":"H He","year":"2024","unstructured":"He H, Zhang JP, Wei ZJ, Lu Y, Zhao YL, Sun RJ. Role of human herpesvirus infection in refractory gastrointestinal graft-versus-host-disease after hematopoietic stem cell transplantation and the diagnosis and treatment thereof. Zhonghua Xue Ye Xue Za Zhi. 2024;45:1016\u201321.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"1453_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/srep25852","volume":"6","author":"G Spielmann","year":"2016","unstructured":"Spielmann G, Bollard CM, Kunz H, Hanley PJ, Simpson RJ. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy. Sci Rep. 2016;6:25852.","journal-title":"Sci Rep"},{"key":"1453_CR163","doi-asserted-by":"crossref","unstructured":"Koldehoff M, Eiz-Vesper B, Maecker-Kolhoff B, Steckel NK, Dittmer U, Horn PA, et al. Long-term follow-up after adoptive transfer of BK-virus-specific T cells in hematopoietic stem cell transplant recipients. Vaccines 2023;11:845.","DOI":"10.3390\/vaccines11040845"},{"key":"1453_CR164","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","volume":"35","author":"I Tzannou","year":"2017","unstructured":"Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35:3547\u201357.","journal-title":"J Clin Oncol"},{"key":"1453_CR165","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","volume":"3","author":"AA Abraham","year":"2019","unstructured":"Abraham AA, John TD, Keller MD, Cruz CRN, Salem B, Roesch L, et al. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Adv. 2019;3:2057\u201368.","journal-title":"Blood Adv"},{"key":"1453_CR166","first-page":"1334","volume":"62","author":"T Kamiya","year":"2021","unstructured":"Kamiya T, Morio T. Viral infections after hematopoietic cell transplantation and treatment with virus-specific T-cell therapies. Rinsho Ketsueki. 2021;62:1334\u201342.","journal-title":"Rinsho Ketsueki"},{"key":"1453_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412211","volume":"15","author":"RS Cooper","year":"2024","unstructured":"Cooper RS, Sutherland C, Smith LM, Cowan G, Barnett M, Mitchell D, et al. EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation. Front Immunol. 2024;15:1412211.","journal-title":"Front Immunol"},{"key":"1453_CR168","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/bloodadvances.2024014937","volume":"9","author":"YD Sarathkumara","year":"2025","unstructured":"Sarathkumara YD, Van Bibber NW, Liu Z, Heslop HE, Rouce RH, Coghill AE, et al. Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025;9:1658\u201369.","journal-title":"Blood Adv"},{"key":"1453_CR169","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1182\/blood-2002-05-1514","volume":"101","author":"S Gottschalk","year":"2003","unstructured":"Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101:1905\u201312.","journal-title":"Blood"},{"key":"1453_CR170","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/mt.2015.91","volume":"23","author":"SG Cho","year":"2015","unstructured":"Cho SG, Kim N, Sohn HJ, Lee SK, Oh ST, Lee HJ, et al. Long-term outcome of extranodal NK\/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs. Mol Ther. 2015;23:1401\u20139.","journal-title":"Mol Ther"},{"key":"1453_CR171","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798\u2013808.","journal-title":"J Clin Oncol"},{"key":"1453_CR172","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","volume":"132","author":"LP McLaughlin","year":"2018","unstructured":"McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, et al. EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018;132:2351\u201361.","journal-title":"Blood"},{"key":"1453_CR173","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","volume":"137","author":"S Naik","year":"2016","unstructured":"Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, et al. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016;137:1498\u2013505.e1.","journal-title":"J Allergy Clin Immunol"},{"key":"1453_CR174","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","volume":"13","author":"X Gu","year":"2024","unstructured":"Gu X, Zhang Y, Zhou W, Wang F, Yan F, Gao H, et al. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. Exp Hematol Oncol. 2024;13:70.","journal-title":"Exp Hematol Oncol"},{"key":"1453_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1086433","volume":"14","author":"T Braun","year":"2023","unstructured":"Braun T, Pruene A, Darguzyte M, Vom Stein AF, Nguyen PH, Wagner DL, et al. Non-viral TRAC-knocked-in CD19(KI)CAR-T and gp350(KI)CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: in vivo cellular dynamics and potency. Front Immunol. 2023;14:1086433.","journal-title":"Front Immunol"},{"key":"1453_CR176","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","volume":"18","author":"C Slabik","year":"2020","unstructured":"Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, et al. CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther Oncolytics. 2020;18:504\u201324.","journal-title":"Mol Ther Oncolytics"},{"key":"1453_CR177","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"key":"1453_CR178","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/hiv.13514","volume":"24","author":"ST Hattenhauer","year":"2023","unstructured":"Hattenhauer ST, Mispelbaum R, Hentrich M, Boesecke C, Monin MB. Enabling CAR T-cell therapies for HIV-positive lymphoma patients - A call for action. HIV Med. 2023;24:957\u201364.","journal-title":"HIV Med"},{"key":"1453_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03040-0","volume":"21","author":"H Li","year":"2023","unstructured":"Li H, Song W, Wu J, Shi Z, Gao Y, Li J, et al. CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK\/T cell lymphoma. BMC Med. 2023;21:330.","journal-title":"BMC Med"},{"key":"1453_CR180","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13046-022-02421-2","volume":"41","author":"X Wang","year":"2022","unstructured":"Wang X, Yu X, Li W, Neeli P, Liu M, Li L, et al. Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022;41:210.","journal-title":"J Exp Clin Cancer Res"},{"key":"1453_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100770","volume":"13","author":"M Zheng","year":"2020","unstructured":"Zheng M, Yu L, Hu J, Zhang Z, Wang H, Lu D, et al. Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer\/T cell lymphoma. Transl Oncol. 2020;13:100770.","journal-title":"Transl Oncol"},{"key":"1453_CR182","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hon.2807","volume":"39","author":"R Cui","year":"2021","unstructured":"Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z, et al. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematol Oncol. 2021;39:75\u201386.","journal-title":"Hematol Oncol"},{"key":"1453_CR183","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1038\/s41375-020-0913-y","volume":"34","author":"R Cui","year":"2020","unstructured":"Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z, et al. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia. 2020;34:3055\u20139.","journal-title":"Leukemia"},{"key":"1453_CR184","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3343\/alm.2023.0388","volume":"44","author":"SJ Kim","year":"2024","unstructured":"Kim SJ, Yoon SE, Kim WS. Current challenges in chimeric antigen receptor T-cell therapy in patients with B-cell lymphoid malignancies. Ann Lab Med. 2024;44:210\u201321.","journal-title":"Ann Lab Med"},{"key":"1453_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55751-4","volume":"16","author":"T Zhu","year":"2025","unstructured":"Zhu T, Xiao Y, Chen Z, Ding H, Chen S, Jiang G, et al. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025;16:262.","journal-title":"Nat Commun"},{"key":"1453_CR186","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.ajpath.2024.04.002","volume":"194","author":"PH Chen","year":"2024","unstructured":"Chen PH, Raghunandan R, Morrow JS, Katz SG. Finding your CAR: the road ahead for engineered T cells. Am J Pathol. 2024;194:1409\u201323.","journal-title":"Am J Pathol"},{"key":"1453_CR187","first-page":"1979","volume":"10","author":"M Huang","year":"2020","unstructured":"Huang M, Deng J, Gao L, Zhou J. Innovative strategies to advance CAR T cell therapy for solid tumors. Am J Cancer Res. 2020;10:1979\u201392.","journal-title":"Am J Cancer Res"},{"key":"1453_CR188","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/jnci\/djz017","volume":"111","author":"BD Hunter","year":"2019","unstructured":"Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111:646\u201354.","journal-title":"J Natl Cancer Inst"},{"key":"1453_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2024","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol. 2024;15:1519671.","journal-title":"Front Immunol"},{"key":"1453_CR190","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","volume":"108","author":"MK Gandhi","year":"2006","unstructured":"Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006;108:2280\u20139.","journal-title":"Blood"},{"key":"1453_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.677027","volume":"12","author":"C Sun","year":"2021","unstructured":"Sun C, Chen XC, Kang YF, Zeng MS. The status and prospects of Epstein-Barr virus prophylactic vaccine development. Front Immunol. 2021;12:677027.","journal-title":"Front Immunol"},{"key":"1453_CR192","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-019-0484-z","volume":"16","author":"M Kannagi","year":"2019","unstructured":"Kannagi M, Hasegawa A, Nagano Y, Kimpara S, Suehiro Y. Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL. Retrovirology. 2019;16:23.","journal-title":"Retrovirology"},{"key":"1453_CR193","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.13302","volume":"169","author":"Y Suehiro","year":"2015","unstructured":"Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study. Br J Haematol. 2015;169:356\u201367.","journal-title":"Br J Haematol"},{"key":"1453_CR194","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, et al. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res. 2014;20:5009\u201322.","journal-title":"Clin Cancer Res"},{"key":"1453_CR195","first-page":"6952","volume":"62","author":"CL Lin","year":"2002","unstructured":"Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 2002;62:6952\u20138.","journal-title":"Cancer Res"},{"key":"1453_CR196","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/annonc\/mdr341","volume":"23","author":"WK Chia","year":"2012","unstructured":"Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH, et al. A phase II study evaluating the safety and efficacy of an adenovirus-\u0394LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol. 2012;23:997\u20131005.","journal-title":"Ann Oncol"},{"key":"1453_CR197","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734471","volume":"12","author":"X Cui","year":"2021","unstructured":"Cui X, Snapper CM. Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases. Front Immunol. 2021;12:734471.","journal-title":"Front Immunol"},{"key":"1453_CR198","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","volume":"31","author":"C Sun","year":"2023","unstructured":"Sun C, Kang YF, Fang XY, Liu YN, Bu GL, Wang AJ, et al. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host Microbe. 2023;31:1882\u201397.e10.","journal-title":"Cell Host Microbe"},{"key":"1453_CR199","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen M, L\u00e9onard P, Sokal EM, Smets F, Haumont M, Mazzu P, et al. Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine. 2007;25:4697\u2013705.","journal-title":"Vaccine"},{"key":"1453_CR200","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bjh.17142","volume":"192","author":"HH Huang","year":"2021","unstructured":"Huang HH, Hsiao FY, Chen HM, Wang CY, Ko BS. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study. Br J Haematol. 2021;192:110\u20138.","journal-title":"Br J Haematol"},{"key":"1453_CR201","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/bjh.19378","volume":"204","author":"R Sciarra","year":"2024","unstructured":"Sciarra R, Merli M, Cristinelli C, Lucioni M, Zibellini S, Riboni R, et al. Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection. Br J Haematol. 2024;204:2242\u201353.","journal-title":"Br J Haematol"},{"key":"1453_CR202","doi-asserted-by":"crossref","unstructured":"Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, et al. A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses 2021;13:2249.","DOI":"10.3390\/v13112249"},{"key":"1453_CR203","doi-asserted-by":"publisher","first-page":"9320","DOI":"10.1007\/s12035-024-04173-w","volume":"61","author":"T Muvenda","year":"2024","unstructured":"Muvenda T, Williams AA, Williams ME. Transactivator of transcription (Tat)-induced neuroinflammation as a key pathway in neuronal dysfunction: a scoping review. Mol Neurobiol. 2024;61:9320\u201346.","journal-title":"Mol Neurobiol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01453-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:03:24Z","timestamp":1772118204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":203,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01453-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}